Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 4,017 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 4,017 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $40.01, for a total transaction of $160,720.17. Following the completion of the transaction, the insider directly owned 87,715 shares in the company, valued at $3,509,477.15. The trade was a 4.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Castle Biosciences Price Performance

NASDAQ CSTL traded up $1.17 during trading hours on Thursday, reaching $42.15. 251,119 shares of the stock traded hands, compared to its average volume of 350,844. Castle Biosciences, Inc. has a 1 year low of $14.59 and a 1 year high of $43.01. The company has a market cap of $1.23 billion, a price-to-earnings ratio of -93.67 and a beta of 1.06. The stock has a 50 day simple moving average of $38.86 and a two-hundred day simple moving average of $28.02. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.47 and a quick ratio of 6.31.

Castle Biosciences (NASDAQ:CSTL) last issued its earnings results on Monday, November 3rd. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.32. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. The company had revenue of $80.55 million for the quarter, compared to analysts’ expectations of $71.06 million. On average, analysts predict that Castle Biosciences, Inc. will post 0.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Castle Biosciences in a report on Monday, December 29th. Zacks Research downgraded Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Friday, January 2nd. BTIG Research lifted their price target on shares of Castle Biosciences from $38.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Lake Street Capital boosted their price target on Castle Biosciences from $35.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Finally, Robert W. Baird increased their target price on Castle Biosciences from $39.00 to $41.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 4th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Castle Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $46.00.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Farther Finance Advisors LLC boosted its holdings in Castle Biosciences by 139,100.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,392 shares of the company’s stock worth $32,000 after buying an additional 1,391 shares during the period. State of Alaska Department of Revenue purchased a new position in shares of Castle Biosciences in the 3rd quarter worth $35,000. CWM LLC increased its holdings in shares of Castle Biosciences by 80.6% in the 3rd quarter. CWM LLC now owns 1,911 shares of the company’s stock worth $44,000 after buying an additional 853 shares during the last quarter. Jones Financial Companies Lllp increased its stake in Castle Biosciences by 10,592.0% during the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after acquiring an additional 2,648 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in shares of Castle Biosciences by 63.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock valued at $57,000 after purchasing an additional 976 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.